CLL Society And BeOne Medicines Expand Partnership With $3 Million Commitment

CLL Society and BeOne Medicines have expanded their partnership through a three-year, $3 million commitment supporting education, digital resources, and community programs for people affected by chronic lymphocytic leukemia and small lymphocytic lymphoma.

The agreement establishes BeOne as a Visionary Partner of CLL Society. It will fund initiatives intended to help patients, care partners, and healthcare professionals understand disease characteristics, biomarker testing, and an increasingly complex range of treatment options.

The organizations plan to expand existing educational programs while developing digital tools that make independent, physician-curated information easier to locate and understand.

Expanding Biomarker Testing Education

A central part of the partnership is the expansion of CLL Society’s Test Before Treat campaign.

The program educates patients, care partners, and healthcare professionals about the importance of biomarker testing before treatment begins. Test results can provide information about genetic mutations and other characteristics that may affect disease risk and treatment decisions.

Chronic lymphocytic leukemia and small lymphocytic lymphoma are closely related blood cancers. They involve the same type of abnormal lymphocytes but are generally distinguished by where those cells are primarily found.

Patient characteristics can vary considerably, including age at diagnosis, general health, access to specialized care, disease progression, and individual risk factors. These differences can affect how clinicians and patients evaluate treatment options.

The Test Before Treat initiative is intended to encourage informed conversations about appropriate testing and explain how mutation status may contribute to more personalized care decisions.

The partnership does not replace medical guidance. Patients will still need to work with qualified healthcare professionals to determine which tests and treatments are appropriate for their individual circumstances.

Developing A New Digital Resource Platform

The three-year commitment will also support a next-generation digital platform for CLL and SLL information.

CLL Society plans to introduce AI-enabled search and personalization features that help patients and care partners identify resources relevant to their needs. The platform will include physician-curated information about the diseases, risk factors, testing, and evolving treatment options.

The goal is to create a trusted destination where community members can access independent educational materials without having to search across multiple disconnected sources.

AI-powered search could help users navigate a growing body of information, but CLL Society will continue to rely on physician curation to support the medical relevance and quality of the resources presented.

The organization’s broader educational strategy is focused on helping patients understand both the strengths and limitations of scientific evidence. This could enable patients and families to prepare more effectively for discussions with their healthcare teams.

Supporting Interviews, Webinars, And Community Programs

BeOne’s funding will also support expert interviews, webinars, and additional community-engagement initiatives.

These programs are designed to keep patients, families, and care partners informed about new research and changes in the CLL and SLL treatment landscape.

CLL Society provides education, advocacy, support, and research resources for patients, families, care partners, and medical professionals. The nonprofit was founded in 2013 by Dr. Brian Koffman, a physician, patient, and advocate, and Patricia Koffman, a care partner and advocate.

The organization’s work is intended to address unmet needs across the CLL and SLL community and help patients become more informed participants in decisions about their care.

BeOne’s Oncology Focus

BeOne Medicines is a global oncology company developing treatments across hematologic cancers and solid tumors.

The company operates across six continents and advances its therapeutic pipeline through internal research capabilities and collaborations. Its expanded partnership with CLL Society focuses specifically on education and access to information rather than the promotion of a single treatment.

The organizations said the partnership is intended to help community members navigate scientific evidence and make decisions appropriate to their individual circumstances in consultation with healthcare professionals.

The $3 million commitment will allow CLL Society to extend existing initiatives while investing in new technology and additional engagement programs over the next three years.

KEY QUOTES:

“No two individuals with CLL or SLL are the same. Each has unique attributes that can impact the disease, from their age at diagnosis to proximity to care, to other health conditions they may have and, of course, the particular risk profile of their disease. Our partnership with CLL Society is about making sure every patient and family has access to all the scientific evidence available at the right time, and the tools to understand it – its strengths and its weaknesses – so they can make the choice that’s right for them. That’s what our core value of putting patients first is really about.”

John V. Oyler, Co-Founder, Chairman, and Chief Executive Officer of BeOne Medicines

“As the needs of the CLL/SLL community continue to evolve, CLL Society is expanding the ways we educate, engage and support patients and families. Our ambition is to reach every person impacted by CLL/SLL with trusted, physician-curated and up-to-date information about their disease, individual risk factors and treatment options. BeOne shares our commitment to helping patients become more informed and confident advocates for their care, and this partnership will help us extend the work we are already doing to more people across the CLL/SLL community. At CLL Society, we believe Smart Patients Get Smart Care™, and we are grateful to BeOne for helping us advance that mission.”

Steve Bloom, President and Chair of CLL Society